Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report

Table of Contents
1 Executive Summary
2 Table of Contents
3 Venture Capital Trends
4 Investors in Biopharmas
5 Regional Breakout
6 Companies with Venture Capital at Risk
7 Key Findings
8 Appendix

List of Tables
Table 1: Q1 2020: Top Companies by Venture Capital Amount
Table 2: Top Therapeutic Areas Receiving Venture Capital (2020)
Table 3: Most Active Investors by Deal Volume: Q1 2020
Table 4: Most Active Investors by Deal Value: Q1 2020
Table 5: 2019: Top Investors by Deal Count
Table 6: 2019 VC Invested by Region (by Recipient HQ Location)
Table 7: Companies Actively Looking to Close Venture Capital Rounds
Table 8: Biopharma Companies with Planned Series A Financing
Table 9: Sample of Biopharma Companies with Expected Series B Financing
Table 10: Sample of Biopharma Companies with Expected Series C Financing
Table 11: Sample of Biopharma Companies with Expected Series D Financing


List of Figures
Figure 1: Venture Capital Deals by Month
Figure 2: Venture Capital Deal Value 2019 FY vs. 2020 ($M)
Figure 3: Deal Volume by Series
Figure 4: Deal Value by Series
Figure 5: VC for Infectious Diseases Drugs Table
Figure 6: Top Investors by Deal Count - Q1 2020 vs. 2019
Figure 7: Spread of COVID-19
Figure 8: Venture Capital Deals in China
Figure 9: Venture Capital Deals in the US